PIONEERING PRECISION IN
|
|
|
|
At Photonic Pharma LLC, we focus on the early phase of drug development - Lead Discovery - using a game-changing technology platform that combines breakthroughs in fluorescence biosensor engineering and fluorescence lifetime detection in living cells. Thus we achieve a dramatic 30-fold increase in the precision of high-throughput screening of small-molecule libraries, with the potential to transform the productivity of pharmaceutical development.
We partner with industrial and academic collaborators, applying our proprietary advancements in structure-based drug-screening technology, to discover novel small-molecule effectors of therapeutically important protein targets. We have assembled a robust and highly integrated network of techniques, concepts, facilities and collaborators to address a wide range of therapeutic goals. |
Photonic Pharma News:
January 2, 2018
Photonic Pharma LLC is pleased to announce that it has signed an expansion and 2-year extension of the research term of its collaboration and license agreement with Bristol-Myers Squibb (NYSE: BMY), effective January 2, 2018.
For other news, please visit the News tab.
January 2, 2018
Photonic Pharma LLC is pleased to announce that it has signed an expansion and 2-year extension of the research term of its collaboration and license agreement with Bristol-Myers Squibb (NYSE: BMY), effective January 2, 2018.
For other news, please visit the News tab.